Prospective studies with a large cohort and comprehensive molecular genetic data are needed to understand the prognosis in patients with AML with various RUNX1 lesions, exclusive of RUNX1T1 fusion and B-cell expression. The gene discussed is RUNX1; the disease is acute myeloid leukemia.